Overview

* Lineage Q3 revenue decreased to $3.7 mln from $3.8 mln in 2024

* Net loss for Q3 increased to $29.75 mln, driven by warrant liabilities

Outlook

* Lineage plans to drive milestone revenue from Roche and Genentech alliance

* Lineage aims to capitalize on investments in cell transplant platform

Result Drivers

* COLLABORATION WITH WDI - Lineage entered a collaboration with William Demant Invest to fund preclinical development of ReSonance, covering up to $12 mln in costs

* MANUFACTURING CAPABILITY - Lineage completed cGMP production runs for OpRegen and OPC1, highlighting scalable production capabilities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$29.75

Income mln

Q3 $7.47

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Lineage Cell Therapeutics Inc ( LCTX ) is $3.00, about 39.5% above its November 5 closing price of $1.82

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)